This article is more than 5 years old. Information may no longer be current.
FDA approves new Baxter peritoneal dialysis system
Click Here to Manage Email Alerts
The United States Food and Drug Administration has granted 510(k) clearance to Baxter International Inc.'s AMIA automated peritoneal dialysis (APD) system with the Sharesource web-based remote connectivity platform. The device is approved to provide peritoneal dialysis for the treatment of end-stage renal disease.
Baxter said it anticipates launching the system in the United States in 2015.
The AMIA APD system uses features such as voice guidance, a touchscreen control panel and the Sharesource two-way connectivity platform. Sharesource allows physicians to access their home patients’ historical treatment data and deliver individual prescriptions remotely. The system also features animated graphics and automated step-by-step instructions..
''PD is an important treatment option for many patients with kidney disease seeking home-based therapy,'' said Jaime Uribarri, MD, Department of Nephrology, Mt. Sinai Hospital, NY. ''We welcome new technology that allows patients to start and administer their physician-prescribed PD therapy at home.''
Read also: Making peritoneal dialysis a success for your patients
The AMIA APD system was developed in collaboration with DEKA Research and Development Corporation -by Rebecca Zumoff